Short Communication: Effect of Etanercept (Enbrel) on Interleukin 6, Tumor Necrosis Factorα, and Markers of Immune Activation in HIV-Infected Subjects Receiving Interleukin 2
- 1 June 2002
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 18 (9), 661-665
- https://doi.org/10.1089/088922202760019365
Abstract
The effect of etanercept, a soluble p75 tumor necrosis factor (TNF) receptor:Fc fusion protein (Enbrel; Immunex, Seattle, WA) on plasma cytokines was evaluated in 11 HIV-infected subjects receiving highly active antiretroviral therapy (HAART) for 28 weeks with or without subcutaneous or intravenous recombinant human interleukin 2 (rhIL-2). Plasma IL-6 and C-reactive protein (CRP) levels increased after rhIL-2 treatment. Etanercept pretreatment attenuated these increases. Median plasma IL-6 levels were 20.29 pg/ml 4 days after rhIL-2 and 7.87 pg/ml 4 days after etanercept and rhIL-2 (p = 0.22); median CRP levels were 78.73 and 46.16 μg/ml, respectively (p = 0.03). An effect on TNF bioactivity could not be assessed as all measurements were below limits of detection. No significant changes were seen in temperature or plasma levels of IL-4, IL-10, IL-12, interferon γ, or HIV-1 RNA levels. All subjects had undetectable or low-level HIV-1 RNA levels before etanercept dosing. One subject died; however, her death was thought to be unrelated to etanercept. Pretreatment with etanercept may blunt activation of IL-6 and CRP expression induced by rhIL-2. The safety and utility of etanercept in HIV-infected persons should be explored further.Keywords
This publication has 14 references indexed in Scilit:
- Etanercept for the Treatment of Human Immunodeficiency Virus-Associated Psoriatic ArthritisMayo Clinic Proceedings, 2000
- Etanercept Therapy in Rheumatoid ArthritisAnnals of Internal Medicine, 1999
- Inhibition of Immunoreactive Tumor Necrosis Factor- by a Chimeric Antibody in Patients Infected with Human Immunodeficiency Virus Type 1The Journal of Infectious Diseases, 1996
- The Tumor Necrosis Factor Ligand and Receptor FamiliesNew England Journal of Medicine, 1996
- Cytokine modulation of HIV expressionSeminars in Immunology, 1993
- Soluble tumor necrosis factor receptor: inhibition of human immunodeficiency virus activation.Proceedings of the National Academy of Sciences of the United States of America, 1993
- C‐reactive protein levels as a direct indicator of interleukin‐6 levels in humans in vivoArthritis & Rheumatism, 1992
- Antigen detection, virus culture, polymerase chain reaction, and in vitro antibody production in the diagnosis of vertically transmitted HIV-1 infectionAIDS, 1991
- Wehi 164 Subclone 13 Assay for Tnf: Sensitivity, Specificity, and ReliabilityImmunological Investigations, 1990
- Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma.The Journal of Experimental Medicine, 1989